The amendment's structure incentivizes Kyverna to draw the remaining $15.0M by year-end to unlock larger tranches ($5-20M B + $40M C) but also triggers minimum revenue covenants. Monitor Kyverna's Q2 2026 10-Q (due by Aug 2026) for cash burn rate and any clinical milestone updates that would enable Term B draw. If Kyverna fails to draw by Dec 2026, it will incur the 1% fee but avoid covenants — a signal of strapped liquidity.
Price Chart
Executive Summary
Kyverna Therapeutics amended its existing loan facility with Oxford Finance LLC to extend availability of the remaining $15.0 million in Term A Loans through December 31, 2026, in exchange for a $187,500 upfront fee. If Kyverna draws the full $15.0 million, the amendment unlocks additional tranches: a $5-20 million Term B Loan tied to clinical milestones (extended to Sept 2027) and two $20 million Term C Loans tied to revenue and clinical milestones (through March 2028), but also triggers minimum revenue covenants starting in H2 2027. The extension buys the company six more months of liquidity runway but flags that Kyverna did not draw the remaining tranche by the original June 30, 2026 deadline, suggesting tighter cash management at a ~$602M market cap clinical-stage biotech.
Key Financial Metrics
Key Facts
- Original Loan Facility: up to $150M total, from Oxford Finance LLC, $25M drawn Nov 2025
- Amendment extends availability of remaining $15.0M Term A Loans from June 30, 2026 to December 31, 2026
- Kyverna paid an upfront cash fee of $187,500 for the extension
- If Kyverna does not draw the $15.0M by Dec 31, 2026, a 1.0% non-utilization fee applies on undrawn amount
- Contingent on drawing the full $15.0M: Term B Loan ($5-20M) extended to earlier of Sept 30, 2027 or 90 days post clinical milestone; Term C Loans ($20M each) available upon revenue and clinical milestones through March 31, 2028
- Minimum revenue covenants begin H2 2027 if Kyverna draws the full $15M, with timing dependent on gross cash proceeds from other capital sources
- If Kyverna does not draw the $15M, original loan terms continue unchanged
Financial Impact
$187,500 upfront fee paid for 6-month extension of $15.0M undrawn Term A availability; 1.0% non-utilization fee if undrawn at Dec 31, 2026 (max $150,000); contingent access to additional $5-20M (Term B) and $40M (Term C) tranches
Risk Factors
- Failure to draw Term A by Dec 31, 2026 triggers a 1% non-utilization fee and blocks access to Term B/C tranches
- Drawing full $15.0M triggers minimum revenue covenants starting H2 2027 — if Kyverna's pre-revenue pipeline does not generate revenue by then, it may breach covenants
- No clinical milestone or revenue milestones disclosed as achieved; Term B/C remain contingent and uncertain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (KYTX) — Batch item 1 | 0001193125-26-298979 |
| Document: 0001193125-26-298979-index-headers.html | 0001193125-26-298979 |
| Document: 0001193125-26-298979-index.html | 0001193125-26-298979 |
| Document: 0001193125-26-298979.txt | 0001193125-26-298979 |
| 8-K Filing (KYTX) — Batch item 5 | 0001193125-26-298979 |
| Document: 0001193125-26-298979-index-headers.html | 0001193125-26-298979 |
| Document: 0001193125-26-298979-index.html | 0001193125-26-298979 |
| Document: 0001193125-26-298979.txt | 0001193125-26-298979 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | SC 13G | $5.83 $6.04 | ▲ +3.60% | ▲ +3.27% | $5.63 (−3.43%) |
Sep 24, 2026 4w ago | 8-K | $6.99 $6.81 | ▼ −2.58% | ▼ −3.12% | $5.63 (−19.46%) |
Aug 11, 2026 11w ago | 8-K | $8.05 $8.08 | ▲ +0.37% | ▼ −0.33% | $5.63 (−30.06%) |
Aug 11, 2026 11w ago | Press Release | $8.05 $8.08 | ▲ +0.37% | ▼ −0.33% | $5.63 (−30.06%) |
Jul 27, 2026 13w ago | 8-K | $7.92 $7.49 | ▼ −5.43% | ▼ −5.67% | $5.63 (−28.91%) |
Jul 9, 2026 15w ago | 8-K | $9.81 $8.49 | ▼ −13.51% | ▼ −13.94% | $5.63 (−42.61%) |
Jun 11, 2026 19w ago | Institutional Cluster | $8.06 $8.15 | ▼ −1.18% | ▲ +0.58% | $5.63 (+30.11%) |
May 4, 2026 25w ago | 8-K | $9.00 $9.21 | ▲ +2.33% | ▲ +1.54% | $5.63 (−37.44%) |
Apr 22, 2026 26w ago | 8-K | $10.23 $8.95 | ▼ −12.51% | ▼ −12.12% | $5.63 (−44.97%) |
Apr 20, 2026 27w ago | Press Release | $11.25 $9.71 | ▼ −13.69% | ▼ −13.04% | $5.63 (−49.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers